Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.
This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Age ≥65 years
Histologically confirmed stage IV NSCLC
Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
Treated with at least ONE cycle of first-line chemotherapy
Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
Incomplete survival data